New Drugs for the Hypertensive Failing Heart
- 610 Downloads
A few important and relevant aspects revealed during a series of basic and clinical research studies have changed the view on hypertension, its treatment, and the prophylaxis of its complications, in particular heart failure.
It has been observed that heart failure prevalence is on the rise, with high mortality rates, including in those undergoing complex therapy for hypertension. Moreover, recent clinical trials have reached surprising conclusions, lowering the threshold for blood pressure readings that have been a reference point to guide hypertension treatment, thus far.
Furthermore, it has been noted that despite the various possibilities to counteract the renin-angiotensin-aldosterone system effects through angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), these agents do not have the expected efficacy on aldosterone secretion. On the contrary, the endogenous secretion of aldosterone increases under treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, giving rise to new challenges.
The relatively new focus on efficiently counteracting the cardiovascular effects of aldosterone is based on the fundamental discoveries from the past decades.
Regardless of aldosterone serum levels (normal or high), aldosterone antagonists are essential agents in the treatment of hypertension, irrespective of the association with heart failure (HF). Moreover, the aldosterone escape phenomenon, meaning the increase in aldosterone secretion sometime after initiating treatment with ACEIs or ARBs, has been also observed after treatment with mineralocorticoid receptor antagonists (MRAs). Consequently, a need to introduce selective inhibitors of aldosterone synthase in the treatment of hypertension was obviated. These agents would prevent both cortisol synthesis inhibition and the increase in the synthesis of particular enzymes that control cortisol secretion. Currently, there is compelling evidence such a compound can be produced and validated in clinical practice. Thus, the 2016 ESC guidelines for diagnosis and treatment of HF mentioned the role of the angiotensin receptor-neprilysin inhibitor (ARNI) where ACEIs/ARBs are not efficient or not well tolerated.
KeywordsHypertension Heart failure New mechanisms New drugs
- 1.Campbell NR, Khalsa T, Lackland DT, Niebylski ML, Nilsson PM, Redburn KA, Orias M, Zhang X-H, Burrell L, Horiuchi M, Poulter NR, Prabhakaran D, Ramirez AJ, Schiffrin EL, Touyz RM, Wang J-G, Weber MA. High blood pressure 2016: why prevention and control are urgent and important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology. J Clin Hypertens (Greenwich). 2016;18(8):714–7.Google Scholar
- 2.Worley SL. Experts provide a glimpse of the new post-SPRINT era of hypertension. PT. 2017;42(2):118–23.Google Scholar
- 6.Freis ED. Historical development of antihypertensive treatment. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press, Ltd.; 1996. p. 2741–51.Google Scholar
- 7.Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, Desai AS, O’Meara E, Fleg JL, Pfeffer MA, Pitt B, Solomon SD. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC Heart Fail. 2017;5(4):241–52.PubMedGoogle Scholar
- 8.Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HAJS, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion J-M, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87.PubMedGoogle Scholar
- 9.Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.PubMedGoogle Scholar
- 11.Laurent S, Steckelings UM. Chapter 29—New drugs under development for cardiovascular prevention BT—early vascular aging (EVA). Boston: Academic Press; 2015. p. 323–34.Google Scholar
- 13.Santese G, Stefanio C, Belletti G, Boiani M, Schipani A, Trane R, Zacà F. The role of aldosterone receptor blocker therapy in hypertension and heart failure. IJC Metab Endocr. 2015;8(Suppl C):34–7.Google Scholar
- 15.Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh C-M, Bizot M-N, Dieterich HA, Howard D, Dole WP. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008;48(11):1323–38.PubMedGoogle Scholar
- 19.Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.PubMedGoogle Scholar
- 20.Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJV, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O’Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Pina IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33(22):2782–95.PubMedGoogle Scholar
- 23.Struthers AD, Unger T. Physiology of aldosterone and pharmacology of aldosterone blockers. Eur Heart J Suppl. 2011;13(Suppl_B):B27–30.Google Scholar
- 31.Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond). 2016;130(2):57–77.Google Scholar
- 32.Burnett H, Earley A, Voors AA, Senni M, McMurray JJV, Deschaseaux C, Cope S. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Heart Fail. 2017;10(1)Google Scholar
- 38.Pellicori P, Urbinati A, Shah P, MacNamara A, Kazmi S, Dierckx R, Zhang J, Cleland JGF, Clark AL. What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? Eur J Heart Fail. 2017;19(6):S47–53.Google Scholar
- 40.Voicu V. Antihypertensive drugs. In: Pharmacology. Craiova: The Medical Publishing Company; 2008. p. 232–47.Google Scholar